Edwards Q3 sales $1.32B; adjusted EPS $0.61 (up 13% YoY); cuts FY22 adjusted EPS guidance to $2.40-$2.50

Edwards Lifesciences Corp

2022-Q3 EPS reported $1.79 revenue$4,034,100,000

GAAP EPS $0.55, adjusted EPS $0.61; $0.07/share charge from discontinuing HARPOON surgical mitral repair.
TAVR sales $862M (+1% reported, +6% cc); TMTT sales $30M; U.S. procedures grew mid-single digits YoY.
2022 adjusted EPS guidance revised to $2.40-$2.50 from prior $2.50-$2.65 range; total sales now expected at low end of $5.35-$5.55B.
Received U.S. FDA and CE Mark for PASCAL Precision; U.S. FDA approval for SAPIEN 3 Ultra RESILIA valve.
Q3 free cash flow $250M; cash and investments $1.7B as of Sept. 30, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edwards Lifesciences Corp updated its quarter ended September 30, 2022 guidance (lowered).

Period: quarter ended September 30, 2022
Guidance: lowered
Result: reported results

Exact text from the filing

On October 27, 2022, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR

accession 0001099800-22-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.